Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €43.54 EUR
Change Today -0.40 / -0.91%
Volume 0.0
8FM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 6:07 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (8FM) Snapshot

Open
€43.46
Previous Close
€43.94
Day High
€43.61
Day Low
€43.46
52 Week High
01/12/15 - €50.50
52 Week Low
05/16/14 - €14.23
Market Cap
1.3B
Average Volume 10 Days
14.7
EPS TTM
--
Shares Outstanding
29.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FOUNDATION MEDICINE INC (8FM)

foundation medicine inc (8FM) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (8FM) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The company provides clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. It also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, foster relationships throughout the oncology community, and develop new clinical and technology products. In addition, the company has a strategic collaboration agreement with WuXi PharmaTech Inc. to provide genomic profiles to biopharmaceutical companies conducting clinical trials; and F. Hoffmann-La Roche Ltd. to develop and commercialize molecular information and genomic analysis products for the treatment of cancer patients. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

293 Employees
Last Reported Date: 03/13/15
Founded in 2009

foundation medicine inc (8FM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $403.9K
President and Chief Operating Officer
Total Annual Compensation: $336.8K
Chief Medical Officer
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

foundation medicine inc (8FM) Key Developments

Foundation Medicine announces management changes

Foundation Medicine, Inc., has appointed Matt Franklin as senior vice president, global marketing. Michael Pellini, M.D., continues as CEO with executive team leadership responsibility and increasing focus on strategic initiatives, corporate vision and long-term growth. Dr. Pellini will also continue as a member of Foundation Medicine's Board of Directors.

Foundation Medicine Announces Board Changes

Foundation Medicine, Inc., has announced proposed changes to its board of directors in connection with its strategic collaboration with Roche. Under the terms of the agreement with Roche, Foundation Medicine's board will increase to nine directors upon the closing of the transaction, including three board designees selected by Roche. In advance of the anticipated transaction closing, Roche has identified its three director designees: Daniel O'Day, Roche Pharmaceuticals Division, COO and member of the Roche corporate executive committee; Sandra J. Horning, M.D., global head, product development and chief medical officer for Roche/Genentech; and Michael D. Varney, Ph.D., head Genentech Research and Early Development. Mr. O'Day, Dr. Horning and Dr. Varney will join Foundation Medicine's current directors including Michael Pellini, M.D., the company's CEO, and its independent members Alexis Borisy (Chairman), Evan Jones, David Schenkein, M.D., and Krishna Yeshwant, M.D. It is anticipated that Brook Byers will step off from the board in connection with the closing.

Foundation Medicine, Inc. Announces Executive Changes

Foundation Medicine, Inc. announced four executive promotions and a new leadership appointment to support and accelerate the company’s United States and global commercial and operational growth plans. Steven Kafka, Ph.D., promoted to president and chief operating officer. Jason Ryan promoted to chief financial officer. Elaine Labrecque promoted to senior vice president, operations. Sarah Larson promoted to senior vice president, human resources. Matt Franklin joins in a newly-created role as senior vice president, global marketing. Michael Pellini, M.D., continues as chief executive officer with executive team leadership responsibility and increasing focus on strategic initiatives, corporate vision and long-term growth. Dr. Pellini will also continue as a member of Foundation Medicine’s Board of Directors. Matt Franklin has joined the company in the newly created role of senior vice president, global marketing, reporting to David J. Daly, chief commercial officer. Mr. Franklin joins Foundation Medicine with two decades of global marketing, portfolio planning, and customer engagement expertise in support of regulated and highly complex medical device and information management products. Mr. Franklin served most recently as vice president, global marketing for Boston Scientific’s $2 billion interventional cardiology division where his strategic marketing, planning and global product launch expertise contributed to the division’s return to revenue growth.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8FM:GR €43.54 EUR -0.40

8FM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genomic Health Inc $30.21 USD 0.00
NeoGenomics Inc $4.72 USD 0.00
Response Genetics Inc $0.45 USD 0.00
Rosetta Genomics Ltd $2.98 USD 0.00
Sequenom Inc $3.90 USD 0.00
View Industry Companies
 

Industry Analysis

8FM

Industry Average

Valuation 8FM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.1x
Price/Book 15.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit www.foundationmedicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.